388 related articles for article (PubMed ID: 20861195)
1. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
4. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
5. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
6. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
7. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
8. Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres.
Roche A; Macdougall IC; Walker RG
Curr Med Res Opin; 2009 Dec; 25(12):2971-6. PubMed ID: 19842997
[TBL] [Abstract][Full Text] [Related]
9. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
11. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
12. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
13. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
14. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
[TBL] [Abstract][Full Text] [Related]
16. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
17. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
Locatelli F; Covic A; Macdougall IC; Wiecek A;
J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
[TBL] [Abstract][Full Text] [Related]
18. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
19. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
20. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
